Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers

Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers

BackgroundImmune checkpoint inhibitors (ICIs) have dramatically improved survival in advanced gastrointestinal (GI) cancer patients, but also resulted in immune-related adverse events (irAEs). This study aimed to evaluate serological biomarkers of irAEs and treatment response in GI cancer patients.P...

Full description

Bibliographic Details
Main Authors:	Yanni Wang, Jianling Zou, Yun Li, Xi Jiao, Yujiao Wang, Na Zhuo, Mengting Gao, Jifang Gong, Jian Li, Xiaotian Zhang, Xicheng Wang, Zhi Peng, Changsong Qi, Zhenghang Wang, Jie Li, Yan Li, Lin Shen, Henghui Zhang, Zhihao Lu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Series:	Frontiers in Immunology
Subjects:	gastrointestinal cancers immune checkpoint inhibitors immune-related adverse events biomarker cytokines
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.987568/full

Similar Items

Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
by: Zhihao Lu, et al.
Published: (2020-08-01)

Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer
by: Zhihao Lu, et al.
Published: (2021-11-01)

Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer
by: Yujiao Wang, et al.
Published: (2022-08-01)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
by: Zhenghang Wang, et al.
Published: (2021-11-01)

Peripheral Blood Biomarkers Predictive of Efficacy Outcome and Immune-Related Adverse Events in Advanced Gastrointestinal Cancers Treated with Checkpoint Inhibitors
by: Zhening Zhang, et al.
Published: (2022-07-01)

The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study
by: Mifen Chen, et al.
Published: (2022-10-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system
by: Yue Li, et al.
Published: (2020-04-01)

Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update
by: Kathryn DeCarli, et al.
Published: (2022-08-01)

Clinical Diagnosis and Treatment of Immune-related Adverse Events in Digestive System Related to Immune Checkpoint Inhibitors
by: Yue LI, et al.
Published: (2019-10-01)

A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
by: Xi Jiao, et al.
Published: (2021-05-01)

The role of T cells in tumor radiotherapy combined with immunotherapy and gastrointestinal adverse events
by: SHI Xiaolin, et al.
Published: (2021-02-01)

Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for Cancer
by: Michael Dougan, et al.
Published: (2024-01-01)

Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications
by: Ding-Kang Wang, et al.
Published: (2021-08-01)

Editorial: Gastrointestinal cancer immunotherapy: from drug resistance mechanisms to overcoming strategies
by: Tao Shi, et al.
Published: (2023-06-01)

Neoadjuvant Immunotherapy for Patients with dMMR/MSI-High Gastrointestinal Cancers: A Changing Paradigm
by: Muhammet Ozer, et al.
Published: (2023-07-01)

Management of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
by: Jiaxin ZHOU, et al.
Published: (2019-10-01)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
by: Jiaxin Zhou, et al.
Published: (2020-01-01)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
by: Junling Zhuang, et al.
Published: (2020-03-01)

Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events
by: Junling ZHUANG, et al.
Published: (2019-10-01)

Clinical Diagnosis and Treatment of Immune-related Adverse Events of Edocrine System Related to Immune Checkpoint Inhibitors
by: Lian DUAN, et al.
Published: (2019-10-01)

Clinical Diagnosis and Treatment Recommendation of Immune-related Adverse Renal Events Related to Immune Checkpoint Inhibitor
by: Wei QIU, et al.
Published: (2019-10-01)

Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer
by: Chie Kudo-Saito, et al.
Published: (2022-09-01)

The Use of Glucocorticoid in the Management of Adverse Effects Related to Immunocheckpoint Inhibitors
by: Hanping WANG, et al.
Published: (2019-10-01)

Gastrointestinal disorders as immune-related adverse events
by: Daniele Balducci, et al.
Published: (2021-04-01)

Use of glucocorticoids in the management of immunotherapy‐related adverse effects
by: Hanping Wang, et al.
Published: (2020-10-01)

DNA damage response-related immune activation signature predicts the response to immune checkpoint inhibitors: from gastrointestinal cancer analysis to pan-cancer validation
by: Junya Yan, et al.
Published: (2024-03-01)

Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment
by: Cynthia Nguyen Tran, et al.
Published: (2019-05-01)

Rheumatic Immune-related Adverse Events and Treatment of Immune Checkpoint Inhibitors
by: ZHANG Xue, et al.
Published: (2020-11-01)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
by: Xiaoyan Si, et al.
Published: (2020-02-01)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
by: Xiaoyin Bai, et al.
Published: (2021-11-01)

Local Delivery of Immunomodulatory Antibodies for Gastrointestinal Tumors
by: Noelia Silva-Pilipich, et al.
Published: (2023-04-01)

Editorial: The role of immune checkpoints in gastrointestinal diseases
by: Xiaofei Shen, et al.
Published: (2023-07-01)

Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis
by: Qi Ai, et al.
Published: (2022-06-01)

Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
by: Michael Dougan
Published: (2017-11-01)

Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor‐associated adverse events
by: Peng Song, et al.
Published: (2020-08-01)

Immune checkpoint inhibitor-induced colitis with endoscopic evaluation in Chinese cancer patients: a single-centre retrospective study
by: Furong Kou, et al.
Published: (2023-11-01)

Recent Advance in Biomarkers for Predicting Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors
by: LI Ying, et al.
Published: (2021-04-01)

Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors
by: Lilong Zhang, et al.
Published: (2023-07-01)

Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
by: Xiaoyan Si, et al.
Published: (2020-03-01)

Upper gastrointestinal tract immune‐related adverse events: Two cases of obstructive complications occurred in immune consolidation therapy after sequential chimeric antigen receptor T cell therapy with autologous hematopoietic stem cell transplantation for refractory/relapsed diffuse large B cell lymphoma
by: Qi Zhang, et al.
Published: (2024-01-01)